Blog

Paolo Tarantino: We need Biomarkers to Tailor Treatment with T-DXd

Paolo Tarantino/X

Jun 3, 2025, 10:50

Paolo Tarantino: We need Biomarkers to Tailor Treatment with T-DXd

Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, reshared a post by Dana-Farber’s Breast Oncology Center, on X:

“Dr. Isaacs made it clear in her DB09 discussion: we need biomarkers to tailor treatment with T-DXd!

At Dana-Farber’s Breast Oncology Center, we’re committed to develop them.

With the help of terrific partners, we tested HER2DX & RPPA in a pilot of 40 pts.

Intriguing results, working on validation.”

Quoting Dana-Farber’s Breast Oncology Center‘s post:

“Metastatic Breast Cancer Poster Session:

Quantitative pre-treatment assessment of trastuzumab deruxtecan (TDXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in Metastatic Breast Cancer (MBC).

Abstract 1032 | Poster Bd 11 | Jun 2, 9-12 PM CDT | Hall A.”

Paolo Tarantino: We need Biomarkers to Tailor Treatment with T-DXd

More posts featuring Paolo Tarantino.

ASCO25 biomarkers cancer Dana-Farber Cancer Institute Dana-Farber’s Breast Oncology Center DB09 fight against cancer Global fight against cancer Harvard Medical School HER2 HER2DX MBC metastatic breast cancer OncoDaily Oncology Paolo Tarantino RPPA T-Dxd topoisomerase Trastuzumab deruxtecan

Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL

15 Posts Not to Miss from the 4th Day of ASCO 2025

15 Posts Not to Miss from the 3rd Day of ASCO 2025

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment